This KDIGO Controversies Conference report clarifies how pharmacists should interpret creatinine shifts during guideline-directed heart failure therapy and where evidence in advanced kidney disease remains absent.
Preventing kidney damage in cancer treatment requires proactive strategies.
Cancer therapy advancements have improved survival but increased kidney damage risks. Nephrotoxicities occur with chemotherapy, targeted agents, and immunotherapies, affecting treatment and quality of life. Collaboration between oncology and nephrology is crucial to balance cancer treatment effectiveness and kidney health. Proactive kidney monitoring is crucial in patients receiving cancer therapies.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Izzedine H, Perazella MA, Kuruvada KM, Jhaveri KD
Citation:Izzedine H, Perazella MA, Kuruvada KM, et al. Cancer therapy and the kidney. Kidney international. 2026;109(6):1125-1136. doi:10.1016/j.kint.2026.01.036
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.